Sign in →

Test Code LAB6690 Haloperidol, Serum

Additional Codes

 

Test Name in EPIC EPIC Test Code Mnemonic Mayo Test ID
HALOPERIDOL, S LAB6690 HALOP HALO

 

Reporting Name

Haloperidol, S

Useful For

Optimizing dosage

 

Monitoring compliance

 

Assessing toxicity

Method Name

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

Performing Laboratory

Mayo Medical Laboratories in Rochester

Specimen Type

Serum Red


Specimen Required


Container/Tube: Red top

Specimen Volume: 1 mL


Specimen Minimum Volume

0.3 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Red Refrigerated (preferred) 28 days
  Ambient  28 days
  Frozen  28 days

Reject Due To

Hemolysis

Mild OK; Gross OK

Lipemia

Mild OK; Gross OK

Icterus

Mild OK; Gross OK

Other

Serum gel tube

Reference Values

HALOPERIDOL

5-16 ng/mL

 

REDUCED HALOPERIDOL

10-80 ng/mL

Day(s) and Time(s) Performed

Tuesday, Thursday; 4 p.m.

CPT Code Information

80173

LOINC Code Information

Test ID Test Order Name Order LOINC Value
HALO Haloperidol, S 87550-0

 

Result ID Test Result Name Result LOINC Value
80339 Haloperidol, S 3669-9
169 Reduced Haloperidol 38364-6

Analytic Time

2 days

Cautions

Potentially interfering drugs include hydroxyzine (interferes with haloperidol), tiagabine (interferes with reduced haloperidol), and quetiapine (interferes with internal standard resulting in artificially low haloperidol).

Method Description

Liquid-liquid extraction with liquid chromatography-tandem mass spectrometry (LC-MS/MS) detection.(Unpublished Mayo method)

Interpretation

Studies show a strong relationship between dose and serum concentration (4); however, there is a modest relationship of clinical response or risk of developing long-term side effects to either dose or serum concentration.

 

A therapeutic window exists for haloperidol; patients who respond at serum concentrations between 5 to 16 ng/mL show no additional improvement at concentrations >16 to 20 ng/mL.(3,5) Some patients may respond at concentrations <5 ng/mL, and others may require concentrations significantly >20 ng/mL before an adequate response is attained.

 

Because of such inter-individual variation, the serum concentration should only be used as 1 factor in determining the appropriate dose and must be interpreted in conjunction with the clinical status.

 

Although the metabolite, reduced haloperidol, has minimal pharmacologic activity, evidence has been presented suggesting that an elevated ratio of reduced haloperidol-to-haloperidol (ie, >5) is predictive of a poor clinical response.(3,6) A reduced haloperidol-to-haloperidol ratio <0.5 indicates noncompliance; the metabolite does not accumulate except during steady-state conditions.

Specimen Retention Time

14 days

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Clinical Information

Haloperidol (Haldol) is a member of the butyrophenone class of neuroleptic drugs used to treat psychotic disorders (eg, schizophrenia). It is also used to control the tics and verbal utterances associated with Tourette's syndrome and in the management of intensely hyperexcitable children who fail to respond to other treatment modalities.

 

The daily recommended oral dose for patients with moderate symptoms is 0.5 to 2.0 mg; for patients with severe symptoms, 3 to 5 mg may be used. However, some patients will respond only at significantly higher doses.

 

Haloperidol is metabolized in the liver to reduced haloperidol, its major metabolite.(1,2)

 

Use of haloperidol is associated with significant toxic side effects, the most serious of which include tardive dyskinesia which can be irreversible, extrapyramidal reactions with Parkinson-like symptoms, and neuroleptic malignant syndrome. Less serious side effects can include hypotension, anticholinergic effects (blurred vision, dry mouth, constipation, urinary retention), and sedation. The risk of developing serious, irreversible side effects seems to increase with increasing cumulative doses over time.(1,3)